Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2

Synucleinopathies are a collection of neurological diseases that are characterized by deposition of α-synuclein aggregates in neurons and glia. These diseases include Parkinson's disease (PD), dementia with Lewy bodies, and multiple system atrophy. Although it has been increasingly clear that α-synuclein is implicated in the pathogenesis of PD and other synucleinopathies, the precise mechanism underlying the disease process remains to be unraveled. The past studies on how α-synuclein exerts pathogenic actions have focused on its direct, cell-autonomous neurotoxic effects. However, recent findings suggested that there might be indirect, non-cell-autonomous pathways, perhaps through the changes in glial cells, for the pathogenic actions of this protein. Here, we present evidence that α-synuclein can cause neurodegeneration through a non-cell-autonomous manner. We show that α-synuclein can be secreted from neurons and induces inflammatory responses in microglia, which in turn secreted neurotoxic agents into the media causing neurodegeneration. The neurotoxic response of microglia was mediated by activation of toll-like receptor 2 (TLR2), a receptor for neuron-derived α-synuclein. This work suggests that TLR2 is the key molecule that mediates non-cell-autonomous neurotoxic effects of α-synuclein, hence a candidate for the therapeutic target.

[1]  E. Masliah,et al.  Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. , 2015, Cell reports.

[2]  Hyunmi Kim,et al.  Control of Inflammatory Responses: a New Paradigm for the Treatment of Chronic Neuronal Diseases , 2015, Experimental neurobiology.

[3]  R. Barker,et al.  Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson’s Disease , 2015, The international journal of neuropsychopharmacology.

[4]  Seokjoong Kim,et al.  ATP13A2/PARK9 Deficiency Neither Cause Lysosomal Impairment Nor Alter α-Synuclein Metabolism in SH-SY5Y Cells , 2014, Experimental neurobiology.

[5]  P. Lucassen,et al.  Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients , 2014, Acta Neuropathologica Communications.

[6]  C. Dobson,et al.  Preconditioning of Microglia by α-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation , 2013, PloS one.

[7]  Hey-kyeong Jeong,et al.  Brain Inflammation and Microglia: Facts and Misconceptions , 2013, Experimental neurobiology.

[8]  J. Nabekura,et al.  Microglia: actively surveying and shaping neuronal circuit structure and function , 2013, Trends in Neurosciences.

[9]  E. Masliah,et al.  Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.

[10]  E. Masliah,et al.  The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.

[11]  Evangelia Emmanouilidou,et al.  Assessment of α-Synuclein Secretion in Mouse and Human Brain Parenchyma , 2011, PloS one.

[12]  M. Mattson,et al.  Toll-like receptor signaling in neural plasticity and disease , 2011, Trends in Neurosciences.

[13]  B. Hyman,et al.  Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  B. Mollenhauer,et al.  Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.

[15]  Ji-Eun Suk,et al.  Non‐classical exocytosis of α‐synuclein is sensitive to folding states and promoted under stress conditions , 2010, Journal of neurochemistry.

[16]  E. Masliah,et al.  Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies* , 2010, The Journal of Biological Chemistry.

[17]  C. Long-Smith,et al.  The influence of microglia on the pathogenesis of Parkinson's disease , 2009, Progress in Neurobiology.

[18]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[19]  W. Schulz-Schaeffer,et al.  Screening of innate immune receptors in neurodegenerative diseases: A similar pattern , 2009, Neurobiology of Aging.

[20]  M. Cookson α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.

[21]  H. Kettenmann,et al.  Microglia: active sensor and versatile effector cells in the normal and pathologic brain , 2007, Nature Neuroscience.

[22]  C. Ferrari,et al.  Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra , 2006, Neurobiology of Disease.

[23]  B. Botterman,et al.  Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease , 2006, The Journal of Neuroscience.

[24]  Smita Patel,et al.  Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates , 2005, The Journal of Neuroscience.

[25]  M. Block,et al.  Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism , 2005, Progress in Neurobiology.

[26]  W. Gan,et al.  ATP mediates rapid microglial response to local brain injury in vivo , 2005, Nature Neuroscience.

[27]  M. Carson Microglia as liaisons between the immune and central nervous systems: Functional implications for multiple sclerosis , 2002, Glia.

[28]  S. Akira,et al.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. , 1999, Immunity.

[29]  G. Halliday,et al.  α-Synucleinopathy phenotypes. , 2014, Parkinsonism & related disorders.

[30]  K. Maguire-Zeiss,et al.  Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease. , 2012, Parkinsonism & related disorders.

[31]  M. Drezner,et al.  Annual Meeting of the American Society for Bone and Mineral Research , 2003 .